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Background: High-risk medication exposure in the elderly is common and associated with increased mortality,
hospitalizations, and emergency department (ED) visits. Skeletal muscle relaxants and antihistamines are high-risk
medications commonly prescribed in elderly patients. The objective of this study was to determine the association
between skeletal muscle relaxants or antihistamines and mortality, hospitalizations, and emergency department visits.
Methods: This study used a new-user, retrospective cohort design using national Veteran Affairs (VA) data from 128
hospitals. Veterans ≥65 years of age on October 1, 2005 who received VA inpatient/outpatient care at least once in
each of fiscal year (FY) 2005 and FY 2006 were included. Exposure to skeletal muscle relaxants and antihistamines was
defined by the National Committee for Quality Assurance Healthcare Effectiveness Data and Information Set measures
for high-risk medications in the elderly. Primary outcomes identified within one year of exposure were death, ED visit,
or hospitalization; ED visits or hospitalizations due to falls and fracture were also assessed. Propensity score matching
(1 to 1 match) was used to balance covariates between exposed patients and non-exposed patients.
Results: In this cohort of 1,807,404 patients 55,566 patients were included in the propensity-matched cohort for skeletal
muscle relaxants and 60,058 patients were included in the propensity-matched cohort for anti-histamines. Mortality was
lower in skeletal muscle relaxants-exposed patients (adjusted odds ratio [AOR] 0.87, 95% CI 0.81-0.94), but risk of
emergency care (AOR 2.25, 95% CI 2.16-2.33) and hospitalization (AOR 1.56, 95% CI 1.48-1.65) was higher for patients
prescribed skeletal muscle relaxants. Similar findings were observed for emergency and hospital care for falls or
fractures. Mortality (AOR 1.93, 95% CI 1.82-2.04), ED visits (AOR 2.35, 95% CI 2.27-2.43), and hospitalizations (AOR 2.21,
95% CI 2.11-2.32) were higher in the antihistamine-exposed group, with similar findings for falls and fractures outcomes.
Conclusion: Skeletal muscle relaxants and antihistamines are associated with an increased risk of ED visits and
hospitalizations in elderly patients. Antihistamines were also associated with an increased risk of death, further validating
the classification of these drug classes as “high risk”.
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A recent population-based study determined that high-
risk medication exposure in the elderly is common and as-
sociated with an increase in mortality, hospitalizations,
and emergency department (ED) visits [1]. Prevention of
drug related problems and inappropriate prescribing in
the elderly have been identified as a priority by the Insti-
tute of Medicine [2]. To address these problems explicit
quality measures have been developed by experts to iden-
tify medications whose risks outweigh potential benefits
[3-6]. The National Committee on Quality Assurance
(NCQA) developed a Healthcare Effectiveness Data and
Information Set (HEDIS) quality measure to examine use
of High Risk Medications in the Elderly (HRME) [6].
The most common HRME drugs prescribed in the
aforementioned study were skeletal muscle relaxants and
first-generation antihistamines [1]. These drugs are po-
tentially dangerous in the elderly due to their side effects
that cause sedation, confusion, and extremity weakness,
all factors associated with falls [3-6]. However, evidence
regarding the clinical impact in prescribing antihista-
mines and skeletal muscle relaxants in older patients are
lacking [7,8].
Therefore, we conducted a retrospective cohort study to
determine whether these commonly prescribed medica-
tions are associated with increased death, ED visits, and
hospitalizations in elderly patients after adjusting for po-
tential confounders and selection bias using propensity-
score matching. Based on prior studies we hypothesized
that individuals prescribed skeletal muscle relaxants and
antihistamines would be more likely to have poor clinical
outcomes when compared to elderly patients not exposed
to these agents.
Methods
This study was approved by the Institutional Review Boards
at the University of Texas Health Science Center at San
Antonio, South Texas Veterans Health Care System, and
the Bedford Veterans Affairs (VA) medical center. Relevant
permissions were obtained to access patient data.
Study design, patients, and setting
This study was a new-user, retrospective cohort design
using national VA administrative data. Veterans were in-
cluded if they were ≥65 years of age on October 1, 2005
and received VA inpatient/outpatient care at least once in
each of fiscal year 2005 (FY 2005) and FY 2006 (October 1,
2004 through September 30, 2006). Patients were excluded
if they were in a VA nursing home or transitional care unit
>60 days in FY 2005 or FY 2006, exposed to skeletal muscle
relaxants or antihistamines prior to FY 2006, or had a sub-
sequent new skeletal muscle relaxant/antihistamine expos-
ure in FY 2007. Each patient was used only once as either a
control or drug exposed subject.Data sources
We used inpatient and outpatient demographic, utiliza-
tion, and comorbidity data from the VA Medical SAS
Datasets. Pharmacy data were extracted from the Phar-
macy Benefits Management (PBM) dataset. Prescription
data in the VA PBM included prescription start date,
generic drug name, and day supply for each drug dis-
pensed. Mortality information was obtained from the VA
Vital Status file, which has a sensitivity of ~98% for vet-
erans’ deaths [9]. Unique patient identifiers linked infor-
mation across these databases.
Exposure definition
Patients exposed to skeletal muscle relaxants or anti-
histamines were identified using the generic drug name
in the VA PBM dataset. Exposure to these agents was
defined by the NCQA HEDIS measures for high risk
medications in the elderly [6]. Antihistamines included
diphenhydramine, hydroxyzine, promethazine, cypro-
heptadine, chlorpheniramine, or tripelennamine. Skeletal
muscle relaxants included methocarbamol, cyclobenzapr-
ine, carisoprodol, chlorzoxazone, metaxalone, or orphe-
nadrine. New users of skeletal muscle relaxants or
antihistamines were defined as those with no exposure in
FY 2005 who were subsequently exposed in FY 2006. The
index date was classified as the day of the first new pre-
scription. Those without exposure (comparator arm) had
an index date of October 1, 2005.
Outcomes
Our primary outcomes were death, ED visit, or hos-
pitalization within one year of the index date. The date of
death was identified using the VA Vital Status files, emer-
gency care was documented using the outpatient VA stop
code pair 102–101 prior to 03/01/2007 or 130 (emergency
care), 131 (urgent care) after that date, and VA hospital
admission and date of admission were identified using
inpatient data. ED visits or hospitalizations due to falls
and fracture within one year of index date were also
assessed using International Classification of Diseases,
Ninth Revision (ICD-9-CM) codes E880.X-E888.X, 820.
X, and 733.14. Patients were identified using an algo-
rithm developed and tested by NCQA.
Covariates
Covariates were selected a priori on the basis of clinical
relevance and previous research [1,10,11].
Demographics
Demographic characteristics (age, sex, race/ ethnicity) were
identified using data from FY 2004-FY 2006. With the
exception of race/ethnicity, these characteristics were well
documented and complete in the medical record. Missing
demographic data are common in VA files; however,
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defined as patients with income under the VA poverty
limit and identified by VA means testing. This limit is
geographically-adjusted and in 2010 was approximately
$29,402.
Clinical characteristics
Clinical characteristics included measures that are asso-
ciated with high disease burden. Higher disease burden,
as defined by more medications, more physical comor-
bidities and psychiatric conditions, place patients at
higher risk for adverse outcomes [2,12]. We also counted
the number of unique medications received during FY
2005, including medications prescribed “as needed”.
Non-VA medications were not included in this count.
ICD-9-CM codes found in VA inpatient and outpatient
data (FY 2004- FY2005) were used to identify individuals
with physical and psychiatric conditions using the Selim
comorbidity indices [13,14]. These indices were devel-
oped to measure chronic disease burden in research in-
volving Veterans. The numbers of chronic disease states
from 30 possible conditions (chronic kidney disease is
included in this count, but not dementia or falls/frac-
tures) were counted to determine the Selim Physical
index. The Selim Psychiatric index includes a count of 6
mental health conditions: schizophrenia, bipolar, depres-
sion, substance use disorder, anxiety and post-traumatic
stress disorder.
Prior healthcare utilization that indicated disease bur-
den was assessed. Previous studies indicate that older
Veterans who receive geriatric care have higher disease
burden and increased risk of HRME exposure; therefore,
individuals who received geriatric care (outpatient or in-
patient) in FY 2005 were identified [11]. Individuals were
identified who had one or more encounters of emer-
gency care or hospital admission in FY 2005 as indica-
tors of disease burden. The number of primary care
visits in FY 2005 was also counted as an indicator of dis-
ease burden and health care utilization [15]. In order to
facilitate interpretation of findings we created categorical
variables for specific continuous measures. Medications
were classified as 0–5, 6–8, 9–11 and 12 or more based
on the empirical distribution from prior research [1].
Physical conditions were classified as zero to one, two to
three, four to five and six or more chronic conditions;
psychiatric conditions as zero, one, and two or more
conditions. Based on the empirical distribution, the
number of primary care visits was classified as having
zero to one, two to four, and five or more visits.
Statistical analyses
We first provided bivariate analysis comparing those
exposed and unexposed in each medication class. In
order to reduce confounding by indication we then usedpropensity score matching to balance measured covariates
between patients exposed to antihistamines or skeletal
muscle relaxants and unexposed patients [16]. Separate lo-
gistic regression models were used to create the propensity
score for each drug group, which modeled the probability
of antihistamine or skeletal muscle relaxant use given all
other study covariates. A routine described by Leuven and
Sianesi was utilized to perform nearest-number matching
with a caliper of 0.0001 [17]. Adjusted odds ratios (AOR)
for the primary and secondary outcomes were then deter-
mined using conditional logistic regression models.
Statistical significance was defined as a two-tailed p
value ≤ 0.05. All analyses were conducted with STATA
12 (College Station, TX).
Results
Baseline characteristics
There were a total of 1,807,404 elderly veteran patients
who met inclusion criteria. The patient sample was mostly
Caucasian (66%) males (98.4%) with ≥2 physical comor-
bidities (71.6%) and taking ≥5 medications (51.4%; Tables 1
and 2). Within 1 year of cohort entry, 81,003 patients
(4.6%) died, 87,118 patients (4.9%) had one or more hos-
pital admissions, 244,106 patients (13.5%) received emer-
gency care; 6,871 patients (0.4%) visited the emergency
department for a fall, and 1,692 (0.09%) patients were hos-
pitalized due to a fall. The composite primary outcome of
death, ED visit or hospitalization within 1-year of cohort
entry occurred in 320,513 patients (17.7%).
Skeletal muscle relaxant exposure
A total of 27,786 (1.5%) patients had a new skeletal
muscle relaxant exposure in FY 2006. The unadjusted
and adjusted odds ratios for the primary and secondary
outcomes for the total cohort are provided in Table 3.
From the 1,807,404 elderly veterans identified, a total
of 55,566 patients were included in the propensity-
matched cohort; 27,783 skeletal muscle relaxant exposed
and 27,783 matched unexposed. Balance between key
covariates after propensity matching is shown on Table 1.
There were no statistically significant differences in mea-
sured characteristics between skeletal muscle relaxant
exposed patients and those not treated.
Table 3 shows the results from the propensity-matched
cohort for the primary and secondary outcomes. The pri-
mary composite outcome of death, ED visits, and hospital-
izations at one year was significantly higher (AOR 2.04,
95% Confidence Interval [CI] 1.97-2.12) in patients ex-
posed to skeletal muscle relaxants vs. patients not ex-
posed. Mortality at one-year was significantly lower in
patients exposed to skeletal muscle relaxants (AOR 0.87,
95% CI 0.81-0.94). ED visits (AOR 2.25, 95% CI 2.16-2.33)
and hospitalization (AOR 1.56, 95% CI 1.48-1.65) at one
year was significantly higher for patients prescribed
Table 1 Patient characteristics-skeletal muscle relaxant











n = 27786 n = 1779618 n = 27783 n = 27783
Age Groups
65-74 16216 (58.4%) 803689 (45.2%) <0.001 16213 (58.4%) 16205 (58.3%) 0.994
75-84 10207 (36.7%) 818252 (46%) 10207 (36.7%) 10210 (36.8%)
85+ 1363 (4.9%) 157677 (8.9%) 1363 (4.9%) 1368 (4.9%)
Gender (female) 668 (2.4%) 28458 (1.6%) <0.001 665 (2.4%) 637 (2.3%) 0.432
Race/Ethnicity
White 19072 (68.6%) 1173582 (66%) <0.001 19072 (68.7%) 19083 (68.7%) 1.00
Black 2841 (10.2%) 110042 (6.2%) 2839 (10.2%) 2838 (10.2%)
Hispanic 1854 (6.7%) 54433 (3.1%) 1853 (6.7%) 1854 (6.7%)
Other 393 (1.4%) 22436 (1.3%) 393 (1.4%) 391 (1.4%)
Unknown/missing 3626 (13.1%) 419125 (23.6%) 3626 (13.1%) 3617 (13%)
Poverty Status
Under the poverty limit 20873 (75.1%) 1038801 (58.4%) <0.001 20870 (75.1%) 20886 (75.2%) 0.895
Number of Medications
0-5 7900 (28.4%) 871000 (48.9%) <0.001 7900 (28.4) 7900 (28.4) 1.00
6-8 6811 (24.5%) 459144 (25.8%) 6810 (24.5%) 6808 (24.5%)
9-11 5601 (20.2%) 249228 (14%) 5601 (20.2%) 5595 (20.1%)
>12 7474 (26.9%) 200246 (11.3%) 7472 (26.9%) 7480 (26.9%)
Number of Physical Comorbidities
0-1 5107 (18.4%) 508737 (28.6%) <0.001 5107 (18.4%) 5123 (18.4%) 0.996
2-3 12041 (43.3%) 844548 (47.5%) 12040 (43.3%) 12040 (43.3%)
4-5 7387 (26.6%) 329098 (18.5%) 7385 (26.6%) 7385 (26.6%)
6+ 3251 (11.7%) 97235 (5.5%) 3251 (11.7%) 3235 (11.7%)
Number of Psychiatric Comorbidities
0 22267 (80.1%) 1555665 (87.4%) <0.001 22267 (80.1%) 22263 (80.1%) 0.993
1 4093 (14.7%) 179695 (10.1%) 4091 (14.7%) 4099 (14.7%)
2+ 1426 (5.1%) 44258 (2.5%) 1425 (5.1%) 1421 (5.1%)
ED visits in 2005 8439 (30.4%) 243864 (13.7%) <0.001 8436 (30.4%) 8441 (30.4%) 0.963
Hospital admissions in 2005 3050 (11%) 96276 (5.4%) <0.001 3049 (11%) 3046 (11%) 0.968
Geriatric visits in 2005 553 (2%) 42550 (2.4%) <0.001 553 (2%) 551 (2%) 0.952
Primary Care visits
0-1 3639 (13.1%) 478963 (26.9%) <0.001 3639 (13.1%) 3639 (13.1%) 0.993
2-4 14736 (53%) 991503 (55.7%) 14736 (53%) 14749 (53.1%)
5+ 9411 (33.9%) 309152 (17.4%) 9411 (33.9%) 9398 (33.8%)
Outcomes
Death within 1 year 1414 (5.1%) 79589 (4.5%) <0.001 1414 (5.1%) 1613 (5.8%) <0.001
Emergency department visit within 1 year 11169 (40.2%) 232937 (13.1%) <0.001 11169 (40.2%) 6399 (23.0%) <0.001
Hospitalization within 1 year 3613 (13%) 83505 (4.7%) <0.001 3613 (13%) 2430 (8.8%) <0.001
Emergency department visit for fall within 1 year 384 (1.4%) 6487 (0.4%) <0.001 384 (1.4%) 176 (0.63%) <0.001
Hospitalization for fall within 1 year 67 (0.2%) 1625 (0.1%) <0.001 67 (0.24%) 46 (0.17%) 0.048
Death emergency department visit or
hospitalization within 1 year (composite)
12365 (44.5%) 308148 (17.3%) <0.001 12356 (44.5%) 7821 (28.2%) <0.001
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Table 2 Patient characteristics-antihistamines
Variable N(%) Unmatched Characteristics Matched Demographic Characteristics (1:1
propensity-scored matching)









n = 30031 n = 1777373 n = 30029 n = 30029
Age Groups
65-74 14853 (49.5%) 805052 (45.3%) <0.001 14851 (49.5%) 14848 (49.5%) 0.993
75-84 12728 (42.4%) 815731 (45.9%) 12728 (42.4%) 12738 (42.4%)
85+ 2450 (8.2%) 156590 (8.8%) 2450 (8.1%) 2443 (8.1%)
Gender (female) 740 (2.5%) 28386 (1.6%) <0.001 738 (2.5%) 722 (2.4%) 0.672
Race/Ethnicity
White 21392 (71.2%) 1171262 (65.9%) <0.001 21392 (71.2%) 21408 (71.3%) 0.995
Black 3197 (10.7%) 109686 (6.2%) 3195 (10.6%) 3196 (10.6%)
Hispanic 1677 (5.6%) 54610 (3.1%) 1677 (5.6%) 1655 (5.5%)
Other 482 (1.6%) 22347 (1.3%) 482 (1.6%) 476 (1.6%)
Unknown/missing 3283 (10.9%) 419468 (23.6%) 3283 (10.9%) 3294 (11%)
Poverty Status
Under the poverty limit 23780 (79.2%) 1035894 (58.3%) <0.001 23778 (79.2%) 23790 (79.2%) 0.602
Number of Medications
0-5 7451 (24.8%) 871449 (49%) <0.001 7451 (24.8%) 7447(24.8%) 1.000
6-8 7045 (23.5%) 458910 (25.8%) 7045 (23.5%) 7049 (23.5%)
9-11 6292 (21%) 248537 (14%) 6292 (21%) 6301 (21%)
>12 9243 (30.8%) 198477 (11.2%) 9241 (30.8%) 9232 (30.7%)
Number of Physical Comorbidities
0-1 5174 (17.2%) 844104 (47.5%) <0.001 5174 (17.2%) 5160 (17.2%) 0.997
2-3 12485 (41.6%) 328371 (18.5%) 12485 (41.6%) 12497 (41.6%)
4-5 8114 (27%) 96228 (5.4%) 8113 (27%) 8127 (27.1%)
6+ 4258 (14.2%) 508670 (28.6% 4257 (14.2%) 4245 (14.1%)
Number of Psychiatric
Comorbidities
0 23260 (77.5%) 1554672 (87.5%) <0.001 23260 (77.5%) 23263 (77.5%) 0.958
1 4906 (16.3%) 178882 (10.1%) 4906 (16.3%) 4919 (16.4%)
2+ 1865 (6.2%) 43819 (2.4%) 1863 (6.2%) 1847 (6.2%)
ED visits in 2005 10345 (34.5%) 241958 (13.6%) <0.001 10343 (34.4%) 10343 (34.4%) 1.000
Hospital admissions in 2005 4472 (14.9%) 94854 (5.3%) <0.001 4471 (14.9%) 4456 (14.8%) 0.863
Geriatric visits in 2005 867 (2.9%) 42236 (2.4%) <0.001 867 (2.9%) 847 (2.8%) 0.624
Primary Care visits
0-1 3975 (13.2%) 478627 (26.9%) <0.001 3975 (13.2%) 3969 (13.2%) 0.997
2-4 15017 (50%) 991222 (55.8%) 15016 (50%) 15018 (50%)
5+ 11039 (36.8%) 307524 (17.3%) 11038 (36.8%) 11042 (36.8%)
Outcomes
Death within 1 year 3685 (12.2%) 77318 (4.4%) <0.001 3684 (12.3%) 2033 (6.8%) <0.001
Emergency department visit within
1 year
13267 (44.2%) 230839 (13%) <0.001 13266 (44.2%) 7562 (25.2%) <0.001
Hospitalization within 1 year 5729 (19.1%) 81389 (4.6%) <0.001 5729 (19.1%) 2895 (9.6%) <0.001
Emergency department visit for fall
within 1 year
383 (1.3%) 6488 (0.4%) <0.001 383 (1.3%) 216 (0.7%) <0.001
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Table 2 Patient characteristics-antihistamines (Continued)
Hospitalization for fall within 1 year 109 (0.4%) 1583 (0.1%) <0.001 109 (0.4%) 56 (0.2%) <0.001
Death emergency department visit
or hospitalization within 1 year
(composite)
16142 (53.8%) 304362 (17.1%) <0.001 16141 (53.8%) 9276 (30.9%) <0.001
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1.84-2.63) and hospitalizations (AOR 1.46, 95% CI 1.001-
2.12) for falls or fractures at one year were also signifi-
cantly higher in patients taking skeletal muscle relaxants.
Antihistamine exposure
There were 30,031 (1.7%) patients exposed to antihista-
mines in FY 2006. Table 4 shows the unadjusted odds
ratios for the primary and secondary endpoints for all
patients included in the study.
For the propensity-matched cohort, we included a
total of 60,058 patients; 30,029 patients exposed to anti-
histamines and 30,029 unexposed. Table 2 shows the
balance among key covariates between antihistamine-
exposed patients and unexposed after propensity match-
ing. After propensity matching there were no statistically
significant differences between the two groups.
Results for the propensity-matched cohort for the pri-
mary and secondary outcomes are displayed on Table 4.
The primary composite outcome at one year was signifi-
cantly higher in patients exposed to antihistamines (AOR
2.60, 95% CI 2.51-2.69). Mortality (AOR 1.93, 95% CI
1.82-2.04), ED visits (AOR 2.35, 95% CI 2.27-2.43), and
hospitalizations (AOR 2.21, 95% CI 2.11-2.32) at one year
were significantly higher in the antihistamine-exposed
group. Fall and fracture related ED visits (AOR 1.78, 95%
CI 1.51-2.11) and hospitalizations (AOR 1.95, 95% CI
1.41-2.69) were also significantly higher at one year in the
antihistamine-exposed group.
Discussion
Our study demonstrated that exposure to either skeletal
muscle relaxants or antihistamines in the elderly were as-
sociated with a greater than two-fold increase in ED visits,






Death 1.14 (1.09-1.21) 0.87 (0.81-0.94)
ED at one year 4.46 (4.36-4.57) 2.25 (2.16-2.33)
Hospitalization at one year 3.04 (2.93-3.15) 1.56 (1.48-1.65)
ED Falls and Fractures 3.83 (3.45-4.25) 2.20 (1.84-2.63)
Hospitalization Falls and Fractures 2.64 (2.07-3.38) 1.46 (1.001-2.12)
Any outcome (composite) 3.82 (3.73-3.92) 2.04 (1.97-2.12)with a 93% increase in mortality. Furthermore, our study
found that exposure to either of these agents increased fall
and/or fracture related ED visits and hospitalizations.
Interestingly, exposure to skeletal muscle relaxants was
associated with a 13% reduction in death. We believe this
finding may be explained by unmeasured confounding due
to the “healthy worker” bias [18]. As an example, physicians
use information such as functional status that is not readily
measured in the medical record or captured in administra-
tive claims data when prescribing potentially dangerous
medications. Although speculative, it is possible that the
elderly patients prescribed skeletal muscle relaxants were
healthier than those not exposed in unmeasured ways.
Moreover, these healthier, more active patients may have
experienced more musculoskeletal injuries that would re-
quire long-term care or closer monitoring by the clinician.
Chronic diseases such as hypertension or diabetes may
have been better controlled under these more closely mon-
itored conditions leading to reduced mortality.
Despite the fact that these medications are listed as in-
appropriate to use in elderly patients, we found the inci-
dence of antihistamine exposure to be 1.7% and skeletal
muscle relaxant exposure to be 1.5%. The incidence of
antihistamine and skeletal muscle relaxant exposure in this
study was similar to reports in the literature [1,11,19,20].
Hospitalization and ED visit rates found in this study are
also similar to findings in previous studies [1,11]. Medica-
tions on the NCQA HEDIS HRME list have rarely been
shown to be associated with ED visits via adverse drug
events (ADE) [12,21]. Most ADEs that elevate the risk of
ED visits in the elderly were derived from a narrow list of
commonly used medications such as antithrombotic and
anti-diabetic drugs [12]. Although ADEs due to skeletal
muscle relaxants or antihistamines may potentially explain






Death 3.08 (2.97-3.19) 1.93 (1.82-2.04)
ED at one year 5.30 (5.18-5.43) 2.35 (2.27-2.43)
Hospitalization at one year 4.91 (4.77-5.06) 2.21 (2.11-2.32)
ED Falls and Fractures 3.53 (3.18-3.91) 1.78 (1.51-2.11)
Hospitalization Falls and Fractures 4.09 (3.37-4.96) 1.95 (1.41-2.69)
Any outcome (composite) 5.62 (5.50-5.76) 2.60 (2.51-2.69)
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for these medications may have other underlying poorly
controlled chronic conditions that lead to poor outcomes
such as hospitalizations and ED visits. HRME has been as-
sociated with increased mortality [1]; however, this study,
to our knowledge, is the first to examine mortality specific-
ally for antihistamines and skeletal muscle relaxants.
Several studies have validated explicit measures of in-
appropriate prescribing in the elderly; however, few have
examined the clinical impact of specific high-risk medica-
tions such as antihistamines and skeletal muscle relaxants
[1,4,5,22-24]. In the 2012 update of the Beers Criteria, the
consensus expert panel strongly recommended the avoid-
ance of first-generation antihistamines and skeletal muscle
relaxants based on only moderate quality of evidence with
the exception of hydroxyzine and promethazine, which
had high quality evidence. This study provides further
support for harmful effects of antihistamines and skeletal
muscle relaxants in elderly patients. This is important
considering 90% of health plans in the United States use
NCQA HEDIS measures to determine provider and health
system performance [25]. These measures take into con-
sideration that pharmacokinetics and pharmacodynamics
of drugs are altered in elderly patients. Diphenhydramine,
a commonly used antihistamine, undergoes substantial
first-pass metabolism and is 80-85% protein bound
[26,27]. Elderly patients on medications that are metab-
olized by the liver, like most antihistamines and skeletal
muscle relaxants, may experience more ADEs due to a
reduction of up to 40% in hepatic volume and blood
flow [28,29]. Drugs that are highly protein bound, such
as diphenhydramine, may also result in more ADEs due
to a decrease in serum albumin by 15-20% in elderly
patients [28,29].
Our study has important limitations. First, variables
not collected for this study may lead to unmeasured
confounding. Our study did not include data, such as
functional status, that are not available in the VA data-
sets. Propensity score matching was performed to bal-
ance covariates and control for important clinical
comorbidities that are risk factors for mortality, hospi-
talizations, ED visits, falls, and fractures. Second, over-
the-counter status of many antihistamines may have
led to an underestimation or misclassification of expos-
ure. Moreover, other antihistamines (e.g., doxylamine
and scopolamine) and skeletal muscle relaxants (e.g.,
baclofen and tizanidine) not listed as HEDIS HRME
may have been used by both exposed and non-exposed
patients. A non-differential misclassification of antihis-
tamine and skeletal muscle relaxant exposure produces
a bias towards the null, potentially making our inter-
pretation of increased risk of events more conservative
[30]. Third, the analysis did not account for exposure
time or time to event. Skeletal muscle relaxants andantihistamines can be used “as needed” for symptoms
rather than scheduled daily like many chronic medica-
tions listed as HEDIS HRME. Moreover, this study de-
termined events within one year from exposure, which
may strengthen the association as compared to choos-
ing a more distal time-point. Fourth, we did not collect
data on drug specific outcome associations. It is un-
known whether a specific drug within either class pre-
dominately contributed to the observed association.
However, the hypothesis was to determine if drug expos-
ure as defined by NCQA HEDIS HRME was associated
with outcomes and may not be powered to determine
drug-specific associations. Additional research is needed
to determine drug-specific associations. Finally, the sam-
ple in the study was representative of a VA population
and had a preponderance of male patients. Therefore,
generalizability to elderly female, non-VA patients is not
clear [31].Conclusion
This study demonstrates that skeletal muscle relaxants
and antihistamines, as listed in the NCQA HEDIS
HRME, are associated with adverse events in elderly pa-
tients, adding further evidence for the validity of the
classification of “high-risk” for these drug classes. Fur-
ther interventions need to be developed to identify pa-
tients at high risk for events and reduce exposure to
these medications while still providing acceptable substi-
tutes for patients.
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